IP Library Granted Patent US 8,765,698
Granted Patent B2
US 8,765,698 · App. 12/699,389 · Granted Jul 1, 2014

Methods and products for reawakening retrocyclins

Inventor: Alexander M. Cole (Chuluota, FL)
Assignee: University of Central Florida Research Foundation, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,765,698
App. No.
12/699,389
Granted
Jul 1, 2014
Kind
B2
Abstract

Products and methods are provided for the restoring the endogenous expression of theta-defensins, such as retrocyclin-1, in mamallian cells. The present invention also includes products and methods for inhibiting sexually transmitted virus entry, e.g., HIV-1 virus entry, into a mammalian cell via, for example, administering to a subject an amount of a read-through mediating agent sufficient to induce exogenous expression of an amount of retrocyclin nonapeptides in the mammalian cell.

Claims (5)

1. A method for inducing the expression of a retrocyclin polypeptide to reduce infection in a mammalian vaginal mucosal cell having a naturally-occurring sequence encoding for the retrocyclin polypeptide, the naturally-occurring sequence having a premature termination codon, the method comprising:

inducing expression of the retrocyclin polypeptide in the mammalian vaginal mucosal cell to reduce infectious agent entry into the mucosal cell by contacting the vaginal mucosal cell with an amount of a read-through mediating agent effective to read-through the premature termination codon and allow for expression of the retrocyclin polypeptide;

wherein the read-through mediating agent comprises at least one of gentamicin and tobramycin.

2. A method for reducing infectious agent entry into a vaginal mucosa of a mammalian subject having a naturally-occurring sequence encoding for a retrocyclin polypeptide, the naturally-occurring sequence having a premature termination codon, the method comprising:

administering to the vaginal mucosa of the mammalian subject an amount of a read-through mediating agent effective to read-through the premature termination codon to induce expression of the retrocyclin polypeptide that reduces infectious agent entry into the vaginal mucosa, wherein the read-through mediating agent comprises at least one of gentamicin and tobramycin.

Assignments (2)
CONFIRMATORY LICENSE Recorded Jun 20, 2016
From: UNIVERSITY OF CENTRAL FLORIDA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 039078/0449 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 19, 2010
From: COLE, ALEXANDER M.
To: UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC.
Reel/Frame 024251/0603 →
Continuity (1)
Related Publication 20110190385A1 · Aug 4, 2011